Burney Co. Lowers Position in Bristol Myers Squibb Company $BMY

Burney Co. decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 61.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 24,708 shares of the biopharmaceutical company’s stock after selling 38,913 shares during the period. Burney Co.’s holdings in Bristol Myers Squibb were worth $1,499,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Kiley Juergens Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 1st quarter worth about $220,000. Canvas Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the first quarter worth about $232,000. Walser Wealth Management Company A Ltd Liability Co bought a new stake in Bristol Myers Squibb during the first quarter worth about $592,000. Cypress Capital LLC grew its holdings in Bristol Myers Squibb by 21.1% in the first quarter. Cypress Capital LLC now owns 46,061 shares of the biopharmaceutical company’s stock worth $2,794,000 after purchasing an additional 8,019 shares during the period. Finally, Meridian Investment Counsel Inc. bought a new position in shares of Bristol Myers Squibb during the first quarter valued at approximately $217,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the subject of several recent research reports. Guggenheim reiterated a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Bank of America lowered their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a report on Monday. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Trading Down 0.7%

Shares of NYSE BMY opened at $57.58 on Thursday. The firm’s 50 day moving average price is $56.84 and its 200-day moving average price is $57.59. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a market cap of $117.58 billion, a PE ratio of 16.17, a P/E/G ratio of 0.17 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.